EUVIMEDEUVIMED entdecken
Open Access

Soluble Epoxide Hydrolase Inhibition Improves Alzheimer’s Disease Hallmarks: Correlation with Peripheral Inflammation and Gut Microbiota Modulation

Júlia Jarne-Ferrer, Christian Griñán-Ferré, Beatrice Jora, Sandra Codony, Lluïsa Miró, Cristina Rosell-Cardona, David Miñana-Galbis, Anna Pérez-Bosque, Santiago Vazquez, Mercè Pallàs

aging and disease · 2025

DOI: 10.14336/ad.2025.0201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift aging and disease, 2025. Verfasst von Júlia Jarne-Ferrer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Therapeutic Chemistry, Universitat de Barcelona, 08028 Barcelona, Spain. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Epoxide Hydrolases, Alzheimer Disease, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting brain inflammation has been proposed as a promising therapeutic strategy to cope with neurodegenerative diseases. Interestingly, accumulating data suggest that the gut microbiota partially exerts its neurodegenerative effects by exacerbating neuroinflammation through increased pathogenic or unhealthy genera that releases different types of cytokines in the periphery. Recently, soluble epoxide hydrolase enzyme (sEH) emerged as a new pharmacological approach for treating Alzheimer's Disease. Treatment with a sEH inhibitor (UB-BJ-02) modified the gut microbiota in the 5xFAD mouse model, increasing health-promoting genera such as Lactobacillus and Limosilactobacillus. By contrast, pro-inflammatory genera (e.g., Bacteroides) were decreased. UB-BJ-02 treatment enhanced the production of anti-inflammatory peripheral mediators in the colon and spleen, such as Il-10. 5xFAD mice treated with UB-BJ-02 showed improved short- and long-term memory and spatial memory compared to 5xFAD control. Furthermore, we found a reduction in neuroinflammatory markers evaluated by immunohistochemical assays, such as GFAP and IBA-1, and gene expression, such as Il-1β, Tnf-a, Il-6, and Trem2, in the brain of 5xFAD-treated mice and a significant decrease in the number of Aβ plaques. T Treatment decreased DRP1 protein levels while increasing OPA1 levels, resulting in improved mitochondrial function corroborated by the elevation of Pgc1-α. Interestingly, a correlation between UB-BJ-02 brain effects and microbiota changes were demonstrated. To validate this correlation, we fed CL4176 AD transgenic strain, with Limosilactobacillus reuteri and Bacteroides rodentium. Consequently, we observed that changes in feeding modified the number of Aβ plaques and neuroinflammatory markers in C. elegans. Therefore, the present study suggested that sEH inhibition with UB-BJ-02 promoted neuroprotective effects, modulating gut microbiota and modifying peripheral and brain pro-inflammatory markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeEpoxide HydrolasesAlzheimer DiseaseEnzyme InhibitorsAnimalsMiceDisease Models, AnimalMice, TransgenicBrainInflammation

Substanzen

Epoxide HydrolasesEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, Toxicology and Therapeutic Chemistry, Universitat de Barcelona, 08028 Barcelona, Spain.
  • Institute of Neurosciences of the Universitat de Barcelona, Passeig de la Vall d'Hebron 171, 08035 Barcelona, Spain.
  • Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed) - National Institute of Health Carlos III, 28029 Madrid, Spain.
  • Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain.
  • Departament de Bioquímica i Fisiologia, Facultat de Farmàcia i Ciències de l'Alimentació and Institut de Nutrició i Seguretat Alimentària, Universitat de Barcelona, 08028 Barcelona, Spain.
  • Secció de Microbiologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028 Barcelona, Spain.

Zitieren

APA

Jarne-Ferrer, J., Griñán-Ferré, C., Jora, B., Codony, S., Miró, L., Rosell-Cardona, C., Miñana-Galbis, D., Pérez-Bosque, A., Vazquez, S., & Pallàs, M. (2025). Soluble Epoxide Hydrolase Inhibition Improves Alzheimer’s Disease Hallmarks: Correlation with Peripheral Inflammation and Gut Microbiota Modulation. aging and disease. https://doi.org/10.14336/ad.2025.0201

Vancouver

Jarne-Ferrer J, Griñán-Ferré C, Jora B, Codony S, Miró L, Rosell-Cardona C, et al. Soluble Epoxide Hydrolase Inhibition Improves Alzheimer’s Disease Hallmarks: Correlation with Peripheral Inflammation and Gut Microbiota Modulation. aging and disease. 2025. doi:10.14336/ad.2025.0201

BibTeX
@article{JarneFerrer2025,
  author = {Jarne-Ferrer, Júlia and Griñán-Ferré, Christian and Jora, Beatrice and Codony, Sandra and Miró, Lluïsa and Rosell-Cardona, Cristina and Miñana-Galbis, David and Pérez-Bosque, Anna and Vazquez, Santiago and Pallàs, Mercè},
  title = {Soluble Epoxide Hydrolase Inhibition Improves Alzheimer’s Disease Hallmarks: Correlation with Peripheral Inflammation and Gut Microbiota Modulation},
  journal = {aging and disease},
  year = {2025},
  doi = {10.14336/ad.2025.0201}
}
Kostenlos starten →